TPST
TPST clinical trials: Tempest Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Tempest Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 3
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
TPST on the catalyst calendar · TPST registry changes
- Primary completion Sep 25, 2024ActualPhase 1NCT04344795Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsTempest Therapeutics · Solid TumorCompletedTPSTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 3NCT06680258A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With...Tempest Therapeutics · Hepatocellular Carcinoma (HCC)Not yet recruitingTPSTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2022ActualPhase 1NCT03829436TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersTempest Therapeutics · Hepatocellular CarcinomaCompletedTPSTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2027Sponsor estimatePhase 1/Phase 2NCT04524871A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver...Hoffmann-La Roche · Advanced Liver CancersActive, not recruitingTPSTCollaboratorADAGCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner